Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference
Molecular Partners presented data on its bispecific Radio-DARPins platform at the Gordon Research Conference, highlighting the technology's ability to engage multiple tumor targets simultaneously to improve precision. The company provided an update on its pipeline, noting that lead candidate MP0712 is currently in a multicenter US Phase 1/2a trial, while second candidate MP0726 is progressing toward first human imaging this year.
Key figures
- Drug Name
- MP0712
- Phase Of Trial
- Phase 1/2a
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.